NASD · Healthcare · Biotechnology · USA
TG Therapeutics Inc is a mid cap company (market value between $2 billion and $10 billion) in the Biotechnology industry.
TG Therapeutics is a biotechnology company that acquires, develops, and commercializes treatments for B-cell diseases. The company markets BRIUMVI, an anti-CD20 monoclonal antibody approved by the FDA for adults with relapsing forms of multiple sclerosis, and has obtained regulatory approvals in several countries outside the U.S.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the TG Therapeutics Inc stock.
Fairly valued: intrinsic value $54.51 per share, market price $53.30, margin of safety 2.2% (as of 2026-10-19).
Discounting its cash flows at 13.0% (average of 2 methods) values the shares at $54.51; the price of $53.30 is 2% below that value.
Leak Score: 38/100 on 12 of 12 signals (On Watch).
17 more funds hold it; the full list is part of the paid plan.
21 more in this industry show a wider margin of safety.
TGTX is fairly valued (as of the 2026-10-19 close). Discounting its cash flows at 13.0% (average of 2 methods) values the shares at $54.51; the price of $53.30 is 2% below that value.
$54.51 per share (as of the 2026-10-19 close), against a market price of $53.30. That is a margin of safety of 2.2%. The value is the average of the valuation methods that apply to this company, recomputed every night after the US close.
38 out of 100, which we rate "On Watch", on 12 of 12 value investing signals.